Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The quarter started with tariff uncertainty, conflicts in the Middle East, rising national debt, and the worst start to a year for the dollar; however, it bounced back to rise 25% from that low by the end of the quarter. The fund returned 2.66% in the first half of 2025. The fund underperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), which were up 5.43% and the Morningstar Moderate Allocation peer group, which rose 5.67%. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, Mairs & Power Balanced Fund highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $8.239 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -5.87%, and its shares lost 29.39% of their value over the last 52 weeks. On September 23, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $52.92 per share.

Mairs & Power Balanced Fund stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its second quarter 2025 investor letter:

“Bio-Techne Corporation (NASDAQ:TECH), which makes high quality ingredients for biopharmaceutical research and production, underperformed due to uncertainty around the industry’s funding environment given recent federal funding cuts and a weak venture capital funding environment. We have taken advantage of the recent weakness to add to our Bio-Techne holdings.”

Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 37 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the second quarter, compared to 34 in the previous quarter. In the fiscal fourth quarter of 2025, Bio-Techne Corporation (NASDAQ:TECH) generated $317 million in revenues, up 3% year-over-year on an organic basis and 4% on reported basis.  While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.